Related by context. All words. (Click for frequent words.) 60 BioMarin Genzyme LLC 60 LFRP 60 RAPTIVA r 59 Forgent intellectual property 59 AnGes MG Inc. 59 QTDP program 58 POTELLIGENT R Technology 58 totaled USD#.#m 58 RECOTHROM ® 58 Qualified Therapeutic Discovery 58 Development OOPD 58 Anticancer Agents 58 BD Biosciences segment 57 Angelini Labopharm 57 TRANSDUR ™ 57 Therapeutic Discovery 57 RAPTIVA R 57 1Q FY# representing 57 Government Qualifying Therapeutic 57 Favourable Changes total 57 Niobe ® 56 LUCENTIS r 56 Noninterest Expense Noninterest expense 56 Licorice Products segment 56 Scantron segment increased 56 RMB#.#million 56 Regulus Therapeutics 56 Oncaspar 56 Lilly ICOS joint venture 56 proprietary BiTE ® 56 DOVONEX 56 novel BiTE antibodies 56 Medarex UltiMAb R 56 Sublicense 56 Integrated Preclinical 55 Translational Science Award 55 NIH NIAID 55 Kleiner Perkins Khosla Ventures 55 EURO#.# [001] 55 HealthStream Learning 55 RESTASIS 55 Eligard R 55 OPANA franchise 55 Project QTDP 55 Vinyls segment 55 Scantron segment decreased 55 3Q FY# representing 55 Euro#.# [002] 55 Discovery Project QTDP 55 EHT AGN 54 Celladon Corporation 54 partner Unither Pharmaceuticals 54 Captisol ® 54 EUR#.#million 54 AZASITE 54 ALN HPN 54 1Q FY# 54 Alnylam #x# 54 FINANCIAL DETAILS 54 NIH SBIR 54 PentaStaph 54 ARCALYST ® rilonacept 54 Micromet proprietary BiTE 54 n#.# [001] 54 Hugoton Properties 54 ALN PCS 54 mg3 web 54 Nanobody ® 54 regadenoson 54 Boehringer Ingelheim MedImmune 54 NIH NHLBI 54 Yidasheng totaled RMB#.# 54 Programmer Paradise segment 54 Currency translation negatively impacted 54 elbion 54 ARCALYST R 53 Regeneron Pharma 53 miRNA therapeutics 53 BioGlue ® 53 Nonaccrual loans totaled 53 OLEPTRO TM 53 HuCAL GOLD R 53 Myocet 53 MCDL 53 AnGes 53 Repligen Corporation 53 Kerastick ® 53 CASING DRILLING TM 53 StromaCel Inc. 53 Crofelemer budesonide foam 53 #compared 53 HuCAL GOLD 53 PLN #.#m [001] 53 BioSeek 53 rxRNA 53 VentiRx Pharmaceuticals 53 Xenonics Announces 53 ferumoxytol Injection 53 glucokinase activator 53 Scaffold Based 53 Ascent Therapeutics 53 Adjusted EBITDA1 53 Nektar PEGylation technology 53 OTCBB HXBM developer 53 Hesperion acquisition 53 rilonacept Injection 53 Thrombin topical Recombinant 53 ArQule Kinase Inhibitor Platform 52 novel antibody therapeutics 52 FOLOTYN ® 52 Janssen AI 52 SKK #.# [001] 52 YTD Fiscal 52 NHGRI Division 52 nine monthsended 52 PLK1 SNALP 52 nicotinic alpha 7 52 Ibis Biosciences 52 SECTA therapy 52 Vernalis plc 52 Ercole Biotech 52 proprietary BiTE antibody 52 using Medarex UltiMAb 52 Relieva 52 ABELCET 52 Qualifying Therapeutic Discovery 52 #.#bn rub [004] 52 Fresenius Biotech 52 product Fentanyl TAIFUN 52 Clinical Diagnostics segment 52 FLW Americas 52 Dacetuzumab 52 MDA Augie Quest 52 Quark Biotech 52 prioryear 52 therapeutic monoclonal antibodies 52 Intravenous CP 52 sameperiod 52 totaled MEUR 52 initiated Phase 1b 52 Foundation MMRF 52 POTELLIGENT R 52 AB OMXS BINV 52 SNALP technology 52 tubulin inhibitor 52 Technology Studies InHealth 52 STRIANT ® 52 BFTDA 52 MabVax 52 Vancocin R 52 HuCAL R 52 MBS AFS increased 52 IRS Qualifying Therapeutic 52 HuCAL antibodies 52 Azactam 52 3Q FY# 52 Curaxin 52 EURO#.# [002] 52 Nascobal ® 52 GH ¢ #,#.# [001] 52 NSF Integrative Graduate 52 Kolltan Pharmaceuticals 52 ELADUR ™ 52 Cardiac Surgery Systems 52 Quark Pharmaceuticals 51 Wellcome Trust Seeding 51 CD# CEA 51 telomerase therapeutic 51 Rexahn licensees 51 Subcutaneous Use 51 Carvedilol Tablets 51 Arno Therapeutics 51 BIIR 51 KeyNote Ventures 51 proprietary phage display 51 2Q FY# representing 51 Nuo Hua 51 Angioblast 51 Translational Science Awards 51 Merck Serono division 51 Gentamicin Surgical Implant 51 Nanobody R 51 Fortical ® 51 Akorn Strides 51 Overall NewMarket 51 quarter offiscal 51 induced macular edema 51 PMPS brand 51 Prometheus Laboratories 51 -Nongsa Point Marina 51 Gross Margin Gross 51 FoldRx Pharmaceuticals Inc. 51 NASDAQ CGEN announced 51 Pharnext 51 Zalypsis 51 Biopump 51 Research Traineeship IGERT 51 UNITS SOLD 51 ZEFFIX 51 Bio Quant Inc. 51 Receives Milestone Payment 51 operatingincome 51 gallium arsenide GaAs substrate 51 ONEOK Partners segment 51 pralatrexate injection folate analogue 51 Agios Pharmaceuticals 51 continuingoperations 51 research anddevelopment 51 Sinuwave 51 Clinical Translational 51 Ribavirin royalties 51 RLEC adjusted EBITDA 51 By ANDREW LOGUE 51 HepeX B 51 Opsona Therapeutics 51 Roche SWX ROG 51 Ziopharm Oncology 51 BioGlue R 51 Nonperforming loans totaled 51 FORMA Therapeutics 51 increaseof 51 REGiMMUNE 51 Loramyc ® 51 Grants Totaling 51 Salix Pharmaceuticals Announces 51 AGY Asia 51 totaled EUR#.#m 51 MARRIOTT REVENUES totaled 51 EnVivo Pharmaceuticals Inc. 51 FHLB advances decreased 51 PENTASA 51 Nabi HB R 51 -Brookfield Asset Management BAMa.TO 51 HuMax 51 Metabasis dependence 51 FoldRx 51 ninemonths ended 51 Urocidin TM 51 Alnylam Biotherapeutics 51 recombinant biopharmaceutical 51 mSEPT9 biomarker 51 RMB2 #.# 51 Galderma SA 51 Syndicate c www.project 51 ARC Linkage 51 Kosan dependence 50 ERYtech 50 SEK#.#m [001] 50 RMB3 #.# 50 UltiMAb 50 UNDT BSM 50 & LSE GLPG 50 Seventh Framework Programme 50 Tyzeka Sebivo 50 SinuNase ™ 50 oncolytic virus therapies 50 Commercialization Agreement 50 Genaera Corporation 50 ASUR regulated 50 Develop Novel 50 Clinical Trial Investigating REOLYSIN 50 4Q FY# 50 GSK '# 50 pentadentate logo R 50 Taligen Therapeutics 50 TPIAO 50 Symphony Dynamo 50 Unfunded pension liability 50 AMPAC ISP Holdings 50 #.#bn rub [005] 50 commercializing Loramyc ® 50 BioMachines 50 taxane derivative 50 InterfeRx 50 BLU U R 50 Tecstar Automotive Group 50 Adult Stem Cell Therapy 50 Ovonic Materials 50 Katonah Debt Advisors 50 Opsona 50 n#.# [002] 50 Olefins segment 50 OncoCyte 50 Nanobody 50 FineTech 50 NITD 50 Wireline adjusted EBITDA 50 NETg acquisition 50 GlycoPEGylated hemostasis compounds 50 noninterest expense totaled 50 Biotica 50 LX# LX# LX# 50 DXL TM 50 SunOpta Foods 50 millioncompared 50 Noninterest expense totaled 50 Symphony ViDA 50 EUR -#.# -#.# [001] 50 SBIR Grant 50 FHLB borrowings decreased 50 Astex Therapeutics 50 millionfor 50 NV Organon 50 MT#/MEDI-# 50 GenWay Biotech 50 RMB#.# [006] 50 Solectron pro forma 50 Aganocide TM 50 LOW PRICE STOCK 50 Individual Annuities segment 50 Bundesministerium für Bildung und 50 Provectus Pharmaceuticals specializes 50 - - Net [052] 50 LifeVantage Announces 50 GVAX ® 50 Integrative Graduate Education 50 LentiVector technology 50 AnaptysBio 50 ZFP Therapeutics 50 Protexia ® 50 Shigamabs ® 50 totaled BRL#.# 50 Peer Reviewed Medical 50 Pentair employs 50 EGP #,#.# 50 Tianwei Yingli 50 NGFN 50 Primera Bioscience 50 Revotar 50 Agri Opportunities 50 Fortical R 50 Magen BioSciences 50 Galenea 50 AFFITOME 50 Explosive Metalworking segment 50 ActivX 50 Retail Leathercraft 50 Rotarix R 50 Tibotec BVBA 50 Invested assets 50 BD Diagnostics segment 50 Heptares 50 Cerenis Therapeutics 50 NASA Terrestrial Ecology 50 Alligator Bioscience AB 50 HuCAL antibody 50 NIGMS 50 Altair Therapeutics 50 commercialize Aganocides 50 Astex 50 Kerastick 50 JCR Pharmaceuticals 50 targeted radiotherapeutic 50 photodisinfection 50 Diatos 50 ESTRASORB R 50 ISV Royalty 50 GCUK generated 50 Ps.2 50 Mining Holdings HKSE 50 Unfavourable Changes 50 FINANCIAL DISCLOSURE 50 Selective Electrochemical Tumor Ablation 50 Taiho Pharmaceutical 49 fracture proppant 49 BioSante licensees 49 drug conjugate ADC 49 protein tyrosine phosphatase 1B 49 Strengthening Institutions 49 NeuroSolutions 49 Nipent R 49 TWD# [001] 49 Prism Pharmaceuticals 49 Teikoku Pharma USA 49 JUVISTA 49 Purse TBA 49 Preotact 49 NASDAQ INGN 49 Genotyping Test 49 Exterran stockholders 49 MD Moross Institute 49 PDE4 inhibitor 49 noninterest expense decreased 49 AMEX RGN 49 CAD#.# [001] 49 Factor VIIa 49 THR beta agonist 49 OREF 49 Unitrin Specialty segment 49 basic immunology transplantation 49 Research MJFF 49 Epiphany Biosciences 49 months endedSeptember 49 Ophthotech 49 Normalized EBITDA 49 PORxin TM platforms 49 Exclusive License 49 BioInvent 49 Recurring royalties 49 immatics 49 thrombopoietin TPO 49 CB2 selective 49 intangible impairments 49 FS Antihemophilic Factor Recombinant 49 novel peptides 49 Nasdaq LEXG 49 RTP #i 49 Captisol 49 HHS Substance Abuse 49 Fovea Pharmaceuticals 49 Evaluation Program CTEP 49 RUB #.# [002] 49 Inhalation Solution 49 Retransmission consent revenue 49 Nycomed GmbH 49 HHSN#C 49 Phenomix Corporation 49 INSPIRE Trial Phase III 49 arGEN X 49 Virosome Biologicals 49 WHO TDR 49 AKIP TM 49 Zor Pharmaceuticals 49 commercialize Aganocide compounds 49 Azithromycin Dispersible Tablets 49 Albugon 49 -Edmund Jelinski 49 BioGeneriX 49 Catalent employs approximately 49 #.#bn rub [003] 49 Oxford Genome Sciences 49 Submitted Pursuant 49 EyeGate Pharma 49 Idec Roche Takeda 49 - #,#.# #,#.# [002] 49 TESARO 49 Loan originations totaled 49 LIFO inventory adjustments 49 - Babelgum Online 49 IMA# 49 Paperboard Packaging segment 49 Influenza Vaccine Production 49 Foundation NSF NCAR 49 Non GAAP Operating Margin 49 CTSAs 49 OMP #R# 49 Alzheimer Immunotherapy Program 49 Accel Partners Mohr Davidow 49 Chlor Alkali segment 49 Nasdaq OMER 49 AirIQ Announces 49 Cardioxyl Pharmaceuticals 49 See CLINICAL PHARMACOLOGY 49 Lovaza TM 49 Orphan Products 49 Vira I. Heinz 49 % unannualized 49 randomly assigned cornea 49 bln.togrogs 49 ZFP Therapeutic ® 49 SORL consolidated 49 AstraZeneca MedImmune 49 QTDP grants 49 Reimbursable costs 49 ACTCellerate 49 Stavros Niarchos Foundation 49 EBITDAO 49 Surgical Adhesive 49 GlaxoSmithKline Amgen Cystic 49 adrenergic regulation 49 RBEG 49 RUR#.#bn approx. USD#.#bn [004] 49 Gujiao facility 49 EnVivo Pharmaceuticals 49 Diabetes Digestive 49 candidate custirsen 49 REVENUE Revenue 49 Donor Advised 49 Unitrin Direct segment 49 Therapeutic Discovery Project 49 iii Ps 49 subsidiary Embryome Sciences 49 Oxy ER 49 Biomarker Discovery Center 49 Etanercept 49 Licensing Agreements 49 sapacitabine CYC# 49 BioThrax ® 49 Flight Attendant Medical 49 Kerastick R 49 SBIR grant 49 MKC# MKC# PP 49 cathepsin K inhibitor 49 Bioengineering NIBIB 49 ended September# 49 Brussels THR 49 Seeding Drug 49 nonoperating expenses 49 Engineered Material Systems 49 DNA RNA Medicines 49 defensin mimetic antimicrobial 49 VentiRx 49 Alzheimer Disease Parkinson Disease 49 Scancell 49 commercialize becocalcidiol patented 49 Theraclone 49 Halotron revenues 49 Loramyc ™ 49 Sangamo ZFP technology 49 X Paralympic Winter 49 PharmaBio Development 49 Polyurethanes segment 49 Euroscreen 49 adjusted1 49 Rs #.# [006] 49 Cathepsin S 49 S2 Therapeutics 49 Nonperforming loans decreased 49 PATH Malaria Vaccine Initiative 49 Liprotamase 49 ZARS Pharma 49 Ps.#.# [002] 49 Zindaclin R 49 Nomura Phase4 Ventures 49 Acceleron Pharma 49 HYVISC R 49 REVENUES Revenues 48 CellCentric 48 ascompared 48 loan originations totaled 48 TRY2 #.# 48 Xcytrin R 48 dihydrochloride Tablets 48 Pulante 48 Neglected Diseases initiative 48 Celladon 48 Non GAAP adjusted EBITDA 48 SmartGrowth Deposits 48 DKK#.# [004] 48 AlloDerm R 48 mertansine 48 Panzem R 48 cosmetic cosmeceutical products 48 Kaketsuken 48 Cephalon GlaxoSmithKline 48 BCR ABL inhibitors 48 Inc. OTCBB VIVK 48 Adenosine Therapeutics 48 date Wholesale Leathercraft 48 oral salmon calcitonin 48 SYCREST 48 millionin 48 Rp#.# trillion [001] 48 InterfeRx TM 48 Defense Congressionally Directed 48 HQK 48 Repliform R revenues 48 PNT# 48 NSF SBIR 48 AcryMed technologies 48 Aegera 48 novel antiviral therapeutics 48 ninemonths 48 AzaSite Xtra 48 Inc. Nasdaq CPRX 48 Kosan epothilone program 48 Creabilis Therapeutics 48 FIPSE 48 selective immunoproteasome inhibitor 48 stock basedcompensation 48 SansRosa 48 Apposite Capital 48 Potelligent TM Technology 48 ARCALYST ® 48 Womacks Adjusted EBITDA 48 Clinical Translational Science 48 Amplimmune 48 anti CD3 monoclonal 48 RMB4 #.# 48 JPY8 48 Omeros Corporation 48 NCAR sponsor 48 MJFF 48 Drug Discovery CEEDD 48 RUR#.#bn approx. [001] 48 Crucell PER.C6 ® 48 Xennex 48 Megace R ES 48 Galapagos NV Euronext GLPG 48 JPY#.# billion [002] 48 XenoPort dependence 48 TKM PLK1 48 Daclizumab 48 HIUBC 48 Sopherion 48 oligonucleotides Manoharan 48 Novexel 48 Platform Hollis Eden 48 HuLuc# 48 MSEK -#.# 48 Targeted Chemotherapy 48 SuperAntibody 48 Taisho Pharmaceuticals 48 Partnered Brands segment 48 proprietary capillary aerosolization 48 NONINTEREST EXPENSE 48 fiscal# 48 using Enhanced Chemiluminescence 48 Rigel R# 48 NASA Exobiology Program 48 JAMIE WELHAM 48 CombinatoRx proprietary 48 mpp files 48 Scantron segment 48 Ibis Therapeutics 48 Applied NeuroSolutions 48 EPSRC 48 Zyngenia 48 #,#,# #,#,# -tuition reciprocity 48 Nektar pulmonary 48 CCR9 antagonist 48 loss NOL carryforward 48 Motorized RV Segment 48 Plexxikon proprietary 48 Selling Expenses 48 Zygogen 48 largest ever amoun 48 CAD#.# [002] 48 Zenyaku Kogyo 48 netsales 48 dacetuzumab SGN 48 Fine Chemicals segment 48 Recurring distributable income 48 Research Traineeship 48 JPY6 48 Sylvie Gregoire President 48 psoriasis rheumatoid arthritis 48 SR#.#bn [001] 48 kidney urologic 48 AusIndustry 48 ALN TTR 48 Traci Arbios 48 Wholesale Leathercraft 48 Friedreich Ataxia FRDA 48 TOFUTTI brand 48 ELESTAT 48 Proximagen 48 Olefins Polyolefins 48 rPA Anthrax Vaccine 48 SCIB1 48 Anaphore 48 Ps.1 #.# 48 DF HCC 48 dacetuzumab collaboration 48 introduced NEUGENE 48 DAPT Study 48 LFB Biotechnologies 48 Noninterest expense decreased 48 Wallace Alexander Gerbode 48 NIHR 48 patented NanoStat TM 48 BioTie 48 Ceflatonin R 48 Othera Pharmaceuticals Inc. 48 NTDDS 48 EpiTherapeutics 48 QuickLicense Server 48 NIH Roadmap 48 Galenea Corp. 48 aripiprazole Abilify 48 Biotechnology Greenhouse 48 Unfunded Commitments 48 Generx TM 48 Phylomer ® 48 LibertyBank Acquisition 48 CVAF 48 Evolva 48 Has Been Awarded 48 Guizhou LLF 48 Cerimon 48 Christopher McDougall Knopf 48 Brightspark Ventures 48 VIBATIV ™ 48 Lipocine 48 Reimbursable revenues 48 OTCBB PYTO FWB ET6 48 EVGN 48 USD#.#m [001] 48 Drug Repositioning 48 Fleximer 48 ImmuneWorks 48 PHAZAR CORP Announces 48 BioWa 48 MNOK #.# 48 Cegedim employs 48 Interest Expense Interest expense 48 Matching Grants 48 eligen R technology 48 en santé du Québec 48 Operating Expense Ratio 48 Enhanze 48 Syntonix 48 LIDODERM 48 comparedto 48 VitiGam 48 Battelle Ventures LP 48 DBM Segment 48 Rwf#.# billion [001] 48 PhD studentships 48 OshKosh wholesale 48 cofinancing 48 foundation Bloomberg Philanthropies 48 #.#/diluted share 48 Association Française contre 48 Nutra Pharma wholly owned 48 PowderMed Ltd. 48 FARESTON ® 48 RMB #,#.# 48 Pancreate 48 PharmaBio 48 Gross Profit Gross 48 7x rollover 48 Alios BioPharma 48 USD#.#m [002] 48 elotuzumab 48 Anchor Therapeutics 48 TELINTRA R 47 Spirogen 47 anincrease 47 Loan originations 47 Pharmacogenetics Research 47 OGAP R 47 5 Yr Avg 47 Apokyn 47 Nexavar sorafenib 47 Intellikine 47 PsychoGenics 47 Lexicon Genetics 47 Avian Transgenic Technology 47 amplify transmit 47 Brentuximab vedotin 47 NIH CounterACT 47 Tesmilifene 47 CysDisplay 47 Nasdaq PCOP 47 Combivir Kivexa 47 GBP#.#m [003] 47 Hubbell Incorporated operates 47 NovaBay Aganocide compounds 47 Infectious Disease NIAID 47 Wenner Gren Foundation 47 WiLAN founded 47 Roche Trimeris 47 TechStart 47 Laiyang Jiangbo 47 adenosine A2A 47 Maccabeats Candlelight 47 Vaccinex 47 BioMimetic seeks 47 Tolerx 47 CHF #.#M 47 Components Segment 47 Lixivaptan 47 Leisura 47 Intevac Photonics revenues 47 #,#,# SUPPLEMENTAL DISCLOSURE [002] 47 totaled EUR#.# 47 dSLIM 47 Rs.#.# Crores [001] 47 extramural research 47 TeleCommunication Systems Receives 47 Network NGFN 47 USD#.#m [008] 47 cardio renal 47 5 lipoxygenase activating 47 EBITDA1 47 TREAT ALS 47 Ventures Emergence 47 Synosia Therapeutics 47 Bayer HealthCare subgroup 47 Alafi Capital 47 Merrimack Pharmaceuticals 47 - Revenues [013] 47 Vegenics 47 PharmaNova 47 Enzo Therapeutics 47 SEK#bn [002] 47 Hardwoods LP 47 -Warhammer Fantasy 47 expenses totaled Ps 47 Epeius Biotechnologies Corporation 47 Oxford Nanopore 47 Preotact ® 47 Ascenta Therapeutics 47 Inc. OTCBB CYKN 47 Archemix Corp. 47 Pandel R 47 Ps.3 47 AMPK activators 47 EPIAO 47 #.Net 47 Broadspire segment 47 Wuhan Generating 47 Alternative Fuels Incentive 47 acyclovir Lauriad R 47 England HEFCE 47 Chemokine 47 Polymer Additives segment 47 #,#,# #,#,# -archival collections 47 Amlodipine Besylate Tablets 47 Fibrosis Foundation Therapeutics 47 Genomics Initiative 47 Fonds de la recherche 47 #.#bln rbl [003] 47 phage display technology 47 ESBATech 47 MFB Corp 47 Semprus BioSciences 47 Syncria R 47 QR#.#bn [007] 47 -Luiza 47 targeted immunotherapies 47 Kerecis 47 VITAGEL 47 H1 FY# [001] 47 Aileron Therapeutics 47 HOPE VI Revitalization 47 Awarded Qualifying Therapeutic 47 Esmee Fairbairn Foundation 47 Exobiology 47 MacroPore 47 OncoVex 47 common neurovascular complication 47 ImmuneRegen BioSciences 47 Dyax phage display 47 MorphoSys antibody 47 ALTROPANE R 47 Viamet 47 Acute Decompensated Heart Failure 47 Amunix 47 LSTA grant 47 HepeX B TM 47 Dhs1 #m 47 Potelligent 47 TIMERx 47 - RevGreencool 47 Maxy G# 47 KNS # 47 reagent disc 47 Ventures Mohr Davidow 47 RUR#.#bn [006] 47 Lexicon Genetics Incorporated 47 SEK #.#M #.# 47 Nasdaq IMGN 47 Kidney Diseases NIDDK 47 Cenomed 47 Refractories segment 47 MoxDuo IV 47 RUB#.#bn [002] 47 AtuRNAi 47 CIMIT 47 Nippon Shinyaku 47 Cenix BioScience 47 Aphios Corporation 47 OTC Bulletin Board TENF 47 Nanotherapeutics 47 Seikagaku Corporation 47 Juvaris BioTherapeutics 47 metabolomics driven 47 NeoVisc R 47 - Revenues [006] 47 Pro forma adjusted EBITDA 47 ALN RSV program 47 MultiCell Technologies 47 quarterended 47 Xantic acquisition 47 HepDirect technology 47 Inpharmatica 47 Catamount Ventures 47 Lipofen 47 CHF#.# [004] 47 Cerner Cerner Cerner Millennium 47 Larry L. Hillblom 47 Screening Trial 47 Biomarker Discovery 47 Excaliard 47 Techteam 47 Kosan motilin agonist 47 JAK3 47 Virginia Tobacco Indemnification 47 Tianyin achieved 47 Transformational Medical 47 PDE# inhibitors 47 AVEO Pharmaceuticals 47 Medarex UltiMAb 47 Astaris joint venture 47 Moctar Diouf #-# 47 Sidney Kimmel Foundation 47 Adnexus Therapeutics 47 Health Journalism Fellowships 47 PLAVIX ® 47 Research Organization BGRO 47 Independent Leg Jackup 47 VASTox 47 3MG MEDIA 47 TEB adjustment 47 generic clopidogrel bisulfate 47 Alvine Pharmaceuticals 47 PF # [002] 47 islets inhabited 47 Innovation CFI 47 Consortium MMRC 47 Qtr Qtr Year 47 Rmb#.# [006] 47 proprietary PEGylation 47 baseband semiconductors 47 BLSI 47 Inhibiton 47 outlicensing 47 Vandetanib 47 group GCIB focuses 47 EGYPTIAN POUND 47 Quark Biotech Inc. 47 theprior 47 OIBDAN declined 47 SBC Excelerator 47 chemogenomics 47 -IPLT#.com 47 Lithia retailed #,# 47 Fabry Disease 47 Phusion Laboratories 47 Immune Tolerance Network 47 IDRI 47 Development Fund ERDF 47 Fifth Framework Programme 47 MSD Wellcome Trust 47 Maternal Obesity 47 purinergic receptors P#X# 47 IV Infusion Therapy 47 SmartGrowth Loans 47 Greenwall Foundation 47 Preakness Impeachment 47 Incentive Grants 47 Locked Nucleic Acid 47 USD#.#m [004] 47 CRM# Protein 47 CHORI 47 Alnara Pharmaceuticals 47 mGluR2 NAM 47 acne impetigo 47 - Revenues [017] 47 rookie Ellis Lankster 47 MXN#.# billion [001] 47 Verastem 47 Translation Jane Campion 47 Genome BC 47 Network HVTN 47 ALS Charitable Remainder 47 OPi 47 @ gn 47 adjusted distributable cash 47 Sopherion Therapeutics 47 Imprime PGG ® 47 motexafin gadolinium Injection 47 #.#mln rub [002] 47 PHX# 47 Mavrix Mutual Funds 46 products BioTime develops 46 Hybridon 46 - RevenuesChhobi 46 Inc. Nasdaq PPHM 46 Regulated Businesses 46 Kinaxo 46 AUD#.# [003] 46 Executive Order #g 46 Airmedia Group Inc 46 GeneICE 46 Health Research NIHR 46 Acceleron Pharma Inc. 46 ZaBeCor 46 SIMCOR 46 Specialty Crop Research 46 Homspera TM 46 Licentia 46 compound KOS 46 John R. Oishei 46 ThermoDox R 46 Fidelity Biosciences 46 Biodefense Division 46 INR#.#m [002] 46 Darinaparsin Zinapar TM 46 Genentech Boehringer Ingelheim 46 nonhazardous materials 46 RPMs flown 46 Rihanna Disturbia vs. 46 Transportation Electrification 46 Multiple Pakfold segment 46 Decentralization Program 46 Covered Loans